Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2018-12-16 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
IMU Meets Endpoints in Phase 1b Gastric Cancer Trial 4 pages 114.5KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement reporting the results of a Phase 1b clinical trial for Imugene's HER-Vaxx gastric cancer vaccine. It details safety, tolerability, dose determination, and preliminary efficacy endpoints. The text includes top-line results, study design, and future Phase 2 plans. It is a clinical trial update and not a full financial report, earnings release, or regulatory filing. The document is longer than 5,000 characters and contains substantive information about the trial outcomes and next steps, which aligns with a Capital/Financing Update or clinical trial progress announcement. However, since it focuses on clinical trial results and development milestones rather than fundraising or capital structure changes, the best fitting category is Regulatory Filings (RNS) as a general announcement of clinical progress and study results that do not fit other specific categories like earnings or annual reports.
2018-12-16 English
Change of Director's Interest Notice - PH 2 pages 183.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options held before and after the change, the nature of the change, and dates. This type of document is a formal notification of personal share transactions by a company director. It is not a financial report, earnings release, or management discussion. The document fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4278 characters, which is consistent with a detailed director's dealing notice. Therefore, the correct classification is DIRS.
2018-11-20 English
Appendix 3B and 708A Notice 14 pages 542.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including shares and unlisted options, their terms, issue prices, and the purpose of the issue. It references ASX rules and compliance requirements related to new securities issuance and quotation. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding new share issues and options, including details on shareholder approvals and quotation applications. This type of document is specifically used to announce new capital raising or share issuance activities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (15,000 characters) and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2018-11-20 English
Change of Director's Interest Notice - LC 2 pages 182.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options held before and after the change, nature of the change, and dates. This type of document is a formal notification of personal share transactions by a company director, which aligns with the definition of Director's Dealing filings. The document is not an annual report, earnings release, or any other financial report, but specifically a report of insider transactions by a director. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2018-11-20 English
Imugene Advances to Phase 2 in Gastric Cancer Trial 4 pages 372.0KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement detailing the progress of Imugene Limited's clinical trial phases for a cancer vaccine. It discusses Phase 1b results, preparations for Phase 2, and clinical trial details. There are no financial statements, regulatory certifications, or voting results. The content is a corporate update on clinical trial progress and future plans, typical of a Capital/Financing Update or general corporate announcement. However, since it focuses on clinical trial progress and not fundraising or capital structure changes, it does not fit CAP. It is not a regulatory filing or report publication announcement since it contains substantive information rather than just a notice. The best fit is a Regulatory Filing (RNS) as a general corporate announcement that does not fit other categories.
2018-11-12 English
AGM Presentation 12 pages 2.1MB
AGM Information Classification · 95% confidence The document is a detailed presentation given by the Managing Director & CEO at an Annual General Meeting (AGM) in November 2018. It includes executive summaries, management team bios, scientific advisory board details, clinical development pipeline, strategic acquisitions, and financial summaries. The content is focused on company strategy, clinical progress, management, and financial highlights, typical of an investor or AGM presentation. There is no indication that this is a full annual report, audit report, or earnings release. The presence of detailed slides and management commentary aligns with an Investor Presentation or AGM Information. Given the header states 'AGM November 2018' and the style is consistent with materials shared at an AGM, the best classification is AGM Information (AGM-R). The document length (9007 characters) supports it being a full presentation rather than a brief announcement or regulatory filing. Confidence is high due to explicit AGM reference and presentation style.
2018-11-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.